| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 26S proteasome non-ATPase regulatory subunit 7, 26S proteasome regulatory subunit RPN8, 26S proteasome regulatory subunit S12, Mov34 protein homolog, Proteasome subunit p40, PSMD7, MOV34L |
| Entrez GeneID | 5713 |
| WB Predicted band size | 37.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PSMD7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 267-295 amino acids from the C-terminal region of human PSMD7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及PSMD7抗体的研究文献摘要概括：
1. **"PSMD7 promotes hepatocellular carcinoma progression through stabilizing c-Myc protein"**
*作者：Li X et al.*
摘要：研究利用PSMD7抗体进行免疫沉淀和Western blot，发现PSMD7通过抑制c-Myc泛素化降解促进肝癌增殖，为肝癌治疗提供潜在靶点。
2. **"Proteasomal PSMD7 is required for maintenance of intestinal stem cells in Drosophila"**
*作者：Chen J et al.*
摘要：通过免疫荧光(PSMD7抗体标记)发现果蝇肠道干细胞中PSMD7维持蛋白酶体活性，敲减导致干细胞分化异常，揭示其在组织稳态中的作用。
3. **"PSMD7 as a prognostic biomarker in breast cancer: A tissue microarray analysis"**
*作者：Wang Y et al.*
摘要：研究使用PSMD7抗体对乳腺癌组织芯片进行免疫组化，发现高表达PSMD7与患者生存率负相关，提示其作为预后标志物的潜力。
*注：以上为文献核心内容概括，实际引用建议通过PubMed/Google Scholar检索原文确认细节。*
The PSMD7 (Proteasome 26S Subunit, Non-ATPase 7) antibody is a research tool used to detect and study the PSMD7 protein, a critical component of the 26S proteasome. The 26S proteasome is a large multi-subunit complex responsible for degrading ubiquitinated proteins, a process essential for maintaining cellular homeostasis, regulating protein turnover, and controlling key processes like cell cycle progression and apoptosis. PSMD7. part of the 19S regulatory particle of the proteasome, plays a role in substrate recognition, deubiquitination, and regulating proteasomal activity.
Antibodies targeting PSMD7 are widely used in molecular biology research to investigate proteasome structure, function, and dysregulation in diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess PSMD7 expression levels, localization, and interactions. Recent studies have linked altered PSMD7 expression to tumor progression, chemoresistance, and neurodegenerative proteinopathies, making it a potential biomarker or therapeutic target.
Available as monoclonal or polyclonal antibodies, PSMD7-specific reagents vary in host species, clonality, and conjugation tags. Researchers select these antibodies based on experimental needs, emphasizing validation in relevant sample types to ensure specificity. Commercial PSMD7 antibodies often include validation data (e.g., knockout cell line controls) to confirm reliability in detecting the ~37 kDa protein. Their applications extend to drug discovery, particularly in developing proteasome inhibitors for cancer therapy.
×
